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After completing this course, the reader will be able to:
1. Outline innovations related to targeted radiation therapy.
2. Describe trials proving an advantage using IMRT.
3. Assess treatment planning modalities and how IMRT fields are designed.
4. Evaluate when there is a toxicity advantage for IMRT.
5. Discern when conventional radiotherapy should be used instead of IMRT.
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ABSTRACT
Intensity-modulated radiation therapy (IMRT) for
head and neck tumors refers to a new approach that
aims at increasing the radiation dose gradient between
the target tissues and the surrounding normal tissues at
risk, thus offering the prospect of increasing the locore-
gional control probability while decreasing the compli-
cation rate. As a prerequisite, IMRT requires a proper
selection and delineation of target volumes. For the lat-
ter, recent data indicate the potential of functional im-
aging to complement anatomic imaging modalities.
Nonrandomized clinical series in paranasal sinuses and
pharyngolaryngeal carcinoma have shown that IMRT
was able to achieve a very high rate of locoregional con-
trol with less morbidity, such as dry-eye syndrome, xe-
rostomia, and swallowing dysfunction. The promising
results of IMRT are likely to be achieved when many
treatment conditions are met, for example, optimal se-
lection and delineation of the target volumes and organs
at risk, appropriate physical quality control of the irra-
diation, and accurate patient setup with the use of on-
board imaging. Because of the complexity of the various
tasks, it is thus likely that these conditions will only be
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INTRODUCTION
During the second half of last century, key technological in-
novations have tremendously modified the daily practice of
radiotherapy, leading to substantial improvements in treat-
ment delivery and outcome. The introduction of linear ac-
celerators (linacs) in the early 1950s, the increasing use of
computed tomography (CT) scanning for target volume de-
lineation from the 1980s on, and more recently, in the late
1990s, the availability of advanced treatment planning sys-
tems together with multileaf collimators have progressively
contributed to a more targeted and conformed dose deliv-
ery, that is, a better dose distribution within the target vol-
umes while sparing surrounding normal tissues. In addition,
linacs are nowadays equipped with electronic portal imag-
ing devices for verification of patient positioning, thus en-
abling a better conformity between the planned dose and the
dose that is actually delivered. All these technical innova-
tions have led on the one hand to delivering a much higher
dose to the target volumes, thus possibly increasing local
tumor control, while on the other hand minimizing the un-
due dose delivered to the surrounding normal tissues, thus
possibly decreasing treatment morbidity.
The introduction of inverse treatment planning systems
with intensity modulation, that is, intensity-modulated ra-
diation therapy (IMRT), over the last few years has brought
another refinement in the ballistics of dose delivery, en-
abling further improvement in dose delivery and treatment
outcome. IMRT is not only a technique for delivering opti-
mized nonuniform beam intensities to a target volume, but
it also provides a new approach to the whole treatment pro-
cedure from patient immobilization to beam delivery. Im-
plementation of IMRT thus requires a knowledge of setup
uncertainties, adequate selection and delineation of target
volumes based on optimal imaging modalities, appropriate
specification and dose prescription regarding dose-volume
constraints, and ad hoc quality control of both the clinical
and physical aspects of the whole procedure.
In head and neck (HN) malignancies, IMRT appears to
be more and more commonly used for routine treatment, es-
pecially in the U.S. [1]. However, only a few randomized
trials have demonstrated its superiority over conventional
treatments [2] and only a few meaningful retrospective
studies are available that demonstrate its potential and its
possible drawbacks. The most convincing data on the supe-
rior therapeutic gain achievable with IMRT are from tu-
mors close to the base of the skull, such as nasopharyngeal
and sinonasal cancers, for which a higher rate of local con-
trol and a lower incidence of complications have been re-
ported in comparison with standard two-dimensional (2D)
techniques in retrospective comparisons [3, 4]. A substan-
tially lower rate of late radiation-induced toxicity, such as
xerostomia, has also been extensively documented follow-
ing the use of IMRT for pharyngolaryngeal squamous cell
carcinomas (SCCs) [2, 5–8]. A few retrospective studies
have also reported that, despite the high conformality in
dose distribution, geographical miss is rather uncommon in
IMRT for pharyngolaryngeal tumors, provided that an ad-
equate selection of target volumes is made [9–12].
Although IMRT shows promise as a radiation procedure
aimed at increasing therapeutic gain, in the HN area, it still
presents a number of challenges and avenues that have yet
to be fully explored. This article presents an overview of the
present clinical data supporting the use of IMRT for HN tu-
mors.
CHALLENGE OF SELECTION AND DELINEATION OF
THE TARGET VOLUMES
Among the various steps of the IMRT process, target vol-
ume selection and delineation represent, without a doubt,
the most dramatic changes in clinical approach compared
with the former 2D treatment of HN tumors. As IMRT al-
lows highly conformal dose distribution to target volumes
of almost any shape, the adequate selection and delineation
of these volumes become of critical importance. An ad-
aptation of the target volumes used in the 2D approach, in
which selection and delineation were determined more
by technical limitations than by oncological consider-
ations and patient anatomy, would likely result in no ben-
efit in terms of dose sparing to nontarget tissues. On the
other hand, an excessively restrictive selection and de-
lineation of target volumes could easily jeopardize the
clinical impact of the highly conformal dose distribu-
tions produced.
Over the past few years, several authors have made rec-
ommendations for a more precise selection of the clinical
target volume (CTV) for both primary tumors and neck
nodes [10, 13, 14]. It is beyond the scope of this review ar-
ticle to discuss these recommendations at length. For pri-
mary tumors, the issue of selection is briefly discussed in
556 IMRT in HN Cancer
the following sections dealing with the various HN sites.
For the neck, comprehensive review of clinical, radiologi-
cal, and pathological data on node distribution for the var-
ious sites within the HN area supports the concept of
selective treatment according to nodal stage. In a nutshell,
for N0 and N1 patients, selective irradiation of level II–IV
or level I–III can be recommended for oropharyngeal, hy-
popharyngeal, and laryngeal primaries, or for oral cavity
primaries, respectively. For nasopharyngeal tumors and for
patients with a neck staged as higher than N2a, comprehen-
sive irradiation of all neck levels is recommended.
Guidelines for the delineation of the various node levels
in the neck have also been proposed, and a series of consen-
sus recommendations endorsed by major North American
(Radiation Therapy Oncology Group [RTOG]) and Euro-
pean (Danish Head and Neck Cancer, European Organiza-
tion for Research and Treatment of Cancer, Groupe
d’Oncologie Radiothérapie Tête et Cou) cooperative
groups has been elaborated for the N0 neck [15, 16]. For the
node-positive and the postoperative neck, further recom-
mendations have been recently proposed [17, 18]. It is be-
yond the scope of this article to discuss these
recommendations at length, but the main philosophy of
these new additional guidelines was to include extra nodal
regions (i.e., retrostyloid area and subclavicular fossa)
and/or extra structures (e.g., muscles or gland) found to be
at risk for microscopic tumor infiltration.
Another important issue regarding target volume delin-
eation is the choice of the optimal imaging modality used
for planning purposes. CT images are typically used be-
cause they allow dose calculation with corrections for tissue
density inhomogeneity. Contrast medium should be rou-
tinely used to allow a much better contrast between normal
tissues and tumors, especially because recent data have
shown that contrast medium does not substantially influ-
ence dose optimization (C. Clark, The Royal Marsden
Hospital, London, personal communication). For naso-
pharyngeal carcinoma, however, magnetic resonance imag-
ing (MRI) has been shown to be superior to CT in reducing
interobserver variability [19, 20]. This advantage of MRI
was not observed in oropharyngeal, laryngeal, and hypo-
pharyngeal tumors [21]. A few groups also investigated the
role of functional imaging with fluorodeoxyglucose-
positron emission tomography (FDG-PET) to delineate
gross tumor volume (GTV) [22, 23]. Daisne et al. [22] as-
sessed the accuracy of FDG-PET in comparison with CT
for GTV delineation in oropharyngeal, hypopharyngeal,
and laryngeal SCC using three-dimensional (3D) registra-
tion of the various imaging modalities. In a subset of laryn-
geal tumors, the imaging modalities could even be
compared with the actual surgical specimen taken as a
“gold standard.” FDG-PET demonstrated higher accuracy
in delineating GTV, with a statistically significant smaller
target volume. Interestingly, this difference in GTV delin-
eation translated into a difference in CTV and planning tar-
get volume (PTV) delineation, which in turn translated into
a difference in dose distribution; the dose was much more
conformed when FDG-PET was used as the primary imag-
ing modality [24].
Although pretreatment contrast-enhanced CT still pres-
ently remains the standard technique used in treatment
planning for HNSCC, it is not unlikely that in the near fu-
ture the introduction of additional modalities may also be
considered, not only before treatment, but also possibly
during treatment to adapt the GTV to the extent of tumor
regression. Furthermore, for PET imaging, tracers other
than FDG for targeting biological pathways for radiation re-
sponse (e.g., proliferation, hypoxia) are under evaluation
[25]. The functional assessment of tumor biology may con-
tribute to the delineation of sub-GTV that could benefit
from a heterogeneous dose distribution [26]. Although very
challenging and extremely promising, these approaches
still need thorough validation before they can be introduced
into routine clinical practice [27].
CLINICAL EVIDENCE FOR THE USE OF IMRT IN
HN TUMORS
IMRT for Nasopharyngeal Carcinoma
Because the nasopharynx is situated near numerous critical
normal organs, that is, the brain stem and optic chiasm,
IMRT is ideal in its attempt to deliver an adequate dose to
the gross tumor while sparing these surrounding normal tis-
sues. IMRT plans involving the nasopharynx require con-
touring the gross disease, which includes the primary gross
tumor as well as any gross nodal disease. Subclinical nodal
CTV involves bilateral coverage of neck nodal levels delin-
eated up to the base of skull to include the retropharyngeal
nodes [4]. For node-negative patients, levels II–V should be
contoured. For node-positive cases, inclusion of level IB
appears reasonable, although convincing data are missing.
In addition to the important at-risk nodal regions, the CTV
should also include the entire nasopharynx, clivus, base of
skull, pterygoid fossa, parapharyngeal space, inferior sphe-
noid sinus, and posterior third of the nasal cavity and max-
illary sinuses (ensuring adequate margin to the ptery-
gopalatine fossae). The CTV that encompass the above
regions can be modified according to tumor (T) stage. A
margin around all CTVs should be added to account for pa-
tient motion and setup errors, that is, the PTV. This margin
is typically 5–6 mm, unless daily imaging and position cor-
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rection are being made, in which case it may be reduced to
a minimum of 3 mm [28].
At Memorial Sloan-Kettering Cancer Center, the imple-
mentation of IMRT for nasopharyngeal cases has resulted
in significant improvements over the traditional and 3D-
conformal radiotherapy (3D-CRT) plans. First, there is bet-
ter coverage of the retropharynx, base of skull, and medial
aspects of the nodal volumes [29]. Xia et al. [30] compared
IMRT treatment plans with conventional treatment plans
for locally advanced nasopharyngeal cancers. They con-
cluded that IMRT provides better tumor target coverage
with significantly better sparing of sensitive normal tissue
structures in the treatment of locally advanced nasopharyn-
geal carcinoma. Another dose distribution study, by Kam et
al. [31, 32] from Hong Kong, compared IMRT with 2D-
radiotherapy (2D-RT) and 3D-CRT treatment plans. Three
patients with different stages, including T1N0, T2bN2, and
T4N2, were compared. In all stages, IMRT was noted to
have significant dose distribution advantages. In early-
stage disease, it provided better parotid gland and temporo-
mandibular joint sparing. In locally advanced disease, it
offered better tumor coverage and normal organ sparing
and permitted room for dose escalation.
The dose distribution advantages seen with IMRT for
nasopharyngeal cancers have also translated into excellent
clinical outcomes. At the most recent American Society of
Clinical Oncology meeting, Kam et al. [33] presented phase
III evidence showing the advantage of IMRT in terms of
improvement in xerostomia when compared with conven-
tional radiotherapy. These data add to the data published by
Pow et al. [2] demonstrating a significant improvement in
quality of life in patients with nasopharyngeal cancer ran-
domized to IMRT compared with those randomized to con-
ventional radiotherapy. In terms of tumor control, the most
mature data on local progression-free rates using IMRT for
nasopharyngeal cancer come from the University of Cali-
fornia at San Francisco (UCSF) (Table 1). With a median
follow-up of 31 months, the 4-year local progression-free
rate was 97% while the 4-year regional progression-free
rate was 98% [4]. Bucci et al. [34] have recently updated the
UCSF experience and included more patients (n  118).
Excellent locoregional progression-free rates were seen.
Other important studies have recently emerged out of Hong
Kong and are also detailed in Table 1. Although single-
institution studies show superb outcomes in terms of sali-
vary preservation as well as locoregional control of disease,
distant metastasis remains a significant issue in all these se-
ries [4, 34–36]. Efforts focused on decreasing the rates of
distant metastasis using targeted biologic agents are under
way by the RTOG.
An RTOG phase II trial using IMRT with or without
chemotherapy for all localized nasopharyngeal cancer has
completed accrual and awaits maturity of follow-up data.
The protocol is an important one, because it tests whether
the ability to achieve excellent control rates in nasopharyn-
geal cancer patients treated with IMRT can be reproduced
in a multi-institutional setting.
The reirradiation of nasopharyngeal cancer has been
commonly used and IMRT offers tremendous dose distri-
bution advantages. Reirradiation is more feasible with
IMRT than with conventional techniques for the many rea-
sons stated above. Lu et al. [37] have recently reported on
their experience with reirradiation using IMRT for recur-
rent nasopharyngeal cancer. Acute toxicity of the skin, mu-
cosa, and salivary glands was acceptable according to
RTOG criteria. Tumor necrosis was seen toward the end of
IMRT in 14 patients (28.6%). At a median follow-up of 9
months, the locoregional control rate was 100%. Although
longer follow-up is necessary, the preliminary toxicity and
local control data for these recurrent cases are promising
[37].
IMRT for Nasal and Paranasal Sinuses
By their location, sinonasal tumors are surrounded by crit-
ical structures, including the frontal and temporal lobes of
the brain, pituitary gland and brainstem, lacrimal glands,
eyes, optic nerves, and chiasm. Using conventional radio-
therapy techniques, the lacrimal apparatus and the optic
pathway structures (retina, optic nerves, chiasm) often re-
ceived doses equal to the target prescription dose. Conven-
tional radiation therapy for sinonasal cancer resulted in
significant ocular toxicity [35, 38–39]. Local control rates
of 70%–90% in stages T1–T2 and 50% in stages T3–T4
were achieved with prescription doses of 56–75 Gy [40].
IMRT allows selective underdosage of organs at risk by
creating concave dose distributions around the optic path-
way structures together with steep cranial, lateral, and cau-
dal gradients outside the PTV to spare the lacrimal
apparatus and the central nervous system. Hypothetically,
selective underdosage could decrease toxicity at unchanged
target prescription doses.
It is unlikely that answers with level I evidence (evi-
dence generated from randomized clinical trials) will
emerge in the foreseeable future because of the rarity of the
disease. A PubMed search on November 14, 2005 using
IMRT and “paranasal sinus” as key words yielded 23 pub-
lications. From these, 17 were on IMRT planning or tech-
nical issues. Of the six clinical publications, three reported
on11 patients, one from UCSF [41] and two from Ghent
University Hospital (GUH) [3, 42].
Using the patient database at GUH, we try to answer the
following questions: How do local control and survival
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rates of IMRT-treated patients compare with those of his-
torical controls? Can IMRT reduce dry-eye syndrome, vi-
sual impairment from retinopathy, and optic neuropathy?
Can IMRT reduce nonocular toxicity?
A heterogeneous group (variety in histology, subsite of
origin, stage, treatment intent) of 62 patients with sinonasal
tumors received IMRT between July 1, 1998 and August
31, 2003. For analysis of survival, local control, and toxic-
ity, we selected patients with stage M0 who underwent R0
resection and postoperative IMRT with curative intent for
adenocarcinoma (n  31) or SCC (n  8). The subsite of
origin was the ethmoid sinus in 30 patients (28 adenocarci-
noma), the maxillary sinus in six (all SCC), and the nasal
cavity in three patients (all adenocarcinoma). Eleven pa-
tients had T4b tumors (2002 International Union Against
Cancer Tumor–Node–Metastasis classification) with inva-
sion of the dura or brain through the cribriform plate. Pa-
tient characteristics and surgery were described in detail by
Duthoy et al. [42].
The 4-year actuarial local control rate after surgery and
IMRT was 80% for patients with T1–4aN0M0 disease.
We compared 28 patients with adenocarcinoma of the eth-
moid sinus who received IMRT with a historical control
group of 30 patients (all R0-resected ethmoid sinus adeno-
carcinoma) treated between 1985 and 1994 with 2D (n 
19) techniques, or treated between 1995 and 1998 with 3D-
conformal noncoplanar techniques (n 11) at prescription
doses of 60–70 Gy (2 Gy/fraction). The 4-year actuarial lo-
cal control and survival rates for those patients are shown in
Table 2.
Fatal relapses occurred within a year after treatment in
all patients (n11 in the IMRT group and n 3 in the his-
torical group) with cribriform plate invasion. The present
IMRT implementation was clearly not able to reverse the
dismal local control rates that are known to exist in stage
T4b disease with cribriform plate invasion. By excluding
patients with cribriform plate invasion, a patient group with
good local control and survival could be selected. No con-
clusions should be drawn regarding the effect of IMRT on
local control as compared with conventional techniques.
In the IMRT group, severe dry-eye syndrome (grade
3, persistent pain) was reported in 2 of 39 patients, includ-
ing a patient with pre-existing unilateral blindness as a re-
sult of orbital tumor invasion for which no attempt was
made to spare the lacrimal apparatus (Table 3). In the his-
torical control, severe dry-eye syndrome occurred in seven
patients, of whom five had been treated by 2D techniques
and two had been treated by 3D techniques (enucleation
was required in one patient). A dose-effect analysis in the
IMRT group showed that even at doses 30 Gy (median
dose to the main lacrimal glands) mild forms of dry-eye
syndrome could be diagnosed.
Bearing in mind a median follow-up of 32 months in
survivors, the data on radiation retinopathy and optic neu-
ropathy should be considered immature. However, we con-
clude that, during this limited follow-up period, two serious
and three mild optic pathway events were recorded. The
maximum-dose constraints of 50 Gy to the retina and 60 Gy
to the optic nerves and chiasm at respective fraction sizes of
approximately 1.5 and 1.7 Gy seem to be close to the max-
imum-tolerated dose for these structures when preservation
of vision is the endpoint.
Thus, the 4-year actuarial local control rate after surgery
and IMRT was80% for patients with T1–T4aN0M0 dis-
ease. Severe dry-eye syndrome could be avoided in almost
all patients if attempted. Severe optic pathway injury oc-
curred in about 5% of patients. We hypothesize that the
maximum-tolerated doses to the retina, optic nerves, and
chiasm might have been reached in the GUH protocol at 50
Gy, 60 Gy, and 60 Gy in 35 fractions, respectively. This hy-
pothesis is being continuously assessed as more patients are
being treated and followed.
IMRT for Oropharyngeal Carcinoma
Most series reporting clinical results of tumor control rates
following IMRT are still quite limited. They are either very
Table 1. Results from series treating nasopharyngeal cancer with IMRT with or without chemotherapy
Study n Staging
Median
follow-up
(months)
Time
point
(years)
Local
control
rate
Regional
control
rate
Distant
metastasis-free
rate
Overall
survival
rate
Lee et al. [4] (UCSF) 67 All stages 31 4 97% 98% 66% 73%
Kwong et al. [34] (Hong Kong) 33 T1N0–N1, M0 24 3 100% 92% 100% 100%
Kam et al. [31, 32] (Hong Kong) 64 All stages 29 3 92% 98% 79% 90%
Wolden et al. [36] (MSKCC) 74 All stages 35 3 91% 93% 78% 83%
Abbreviations: IMRT, intensity-modulated radiation therapy; M, metastasis; MSKCC, Memorial Sloan-Kettering Cancer
Center; N, node; T, tumor; UCSF, University of California at San Francisco.
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heterogeneous regarding tumor sites and stages [9, 11, 12,
41, 43] or have relatively small patient numbers [8, 41], and
all series suffer from a relatively short follow-up. Potential
patient selection factors are probably the most important is-
sues that should be considered in assessing outcome in ret-
rospective series of IMRT. IMRT is far more complex and
time-consuming than conventional radiotherapy. It is likely
that different selection factors play a role at each institution:
patients who cannot tolerate lengthy treatment, those
judged to be too sick to benefit from complex therapy, those
requiring urgent start of therapy, etc., may be selected to re-
ceive more simple, conventional treatment. These factors
make any attempt to compare the results of different IMRT
series, or even series of IMRT with series of conventional
RT, futile. Notwithstanding these limitations, all series of
IMRT outcome have reported outstanding locoregional
control rates for oropharyngeal cancer [11, 12, 43– 45].
These series reported 2-year locoregional tumor control
rates of 90%–98% for patient populations consisting
mainly of stage III–IV tumors. However, these series con-
tain a mixture of definitively and postoperatively treated
patients and variable ratios of patients treated with concur-
rent chemoirradiation or radiotherapy alone. The series
from Michigan included patients with various non-naso-
pharyngeal tumor sites; having an oropharyngeal cancer
site was the most significant predictor of local/regional tu-
mor control.
Some of the most reliable information gained from clin-
ical series of IMRT for HN cancer in general and oropha-
ryngeal cancer in particular relates to the pattern of tumor
recurrences relative to the targets and the locally delivered
doses. These data allow an assessment of the adequacy of
target selection and delineation. In all reported cases, it
seems that careful selection and delineation of the targets
resulted in very few or no marginal or out-of-field recur-
rences. de Arruda and colleagues reported that all recur-
rences in their series were in-field [45]. Chao and
colleagues reported that most marginal recurrences oc-
curred in the lower neck, which was treated with an anterior
field that was matched to the IMRT-treated upper neck
[11]. At the University of Michigan, where the majority of
patients had oropharyngeal cancer, almost all recurrences
occurred in-field, in high-risk volumes that had received the
full prescribed doses [9]. An update of this study included
133 patients, 80 of whom had oropharyngeal cancer [12].
At a median follow-up of 32 months 21 locoregional fail-
ures (16%) occurred. Of these, 17 recurred in-field and four
were marginal recurrences. After the first analysis of mar-
ginal recurrences [9], modifications in target delineation
principles were made, following which no additional mar-
ginal recurrences were noted [12]. This demonstrates a
learning curve, characteristic of complex therapies, and the
likelihood that treatment outcome improves as the experi-
ence of the team using IMRT increases. Of note, no mar-
ginal recurrence occurred in the contralateral N0 neck,
where the cranialmost target included the subdigastric
nodes. The definition of the top of level II in the contralat-
eral N0 neck in patients with oropharyngeal cancer has been
the level at which the posterior belly of the digastric muscle
is crossed by the jugular vein [9, 12, 13]. This definition en-
sures that the jugulodigastric nodes, being the topmost level
II nodes draining oropharyngeal cancer according to Rou-
viere [46], are irradiated. This definition coincides with the
transverse process of the C1 vertebral body, which marks
the top of level II according to consensus guidelines [15].
The lack of recurrences cranial to this level in the Michigan
and the Leuven series [9, 47], which used the same defini-
tion for the cranialmost level II, is reassuring and is in ac-
Table 2. Local control and survival of ethmoid sinus adenocarcinoma
IMRT group
1998–2003
Historical control
1998–2003 p-value
n of patients 28 30
Cribriform plate invasion 11 3
Median follow-up (months) 31 86
Four-year actuarial survival rate
All patients 59% 66% .25
No cribriform plate invasion 94% 73% .29
Four-year actuarial local control rate
All patients 63% 63% .72
No cribriform plate invasion 86% 70% .28
Dry-eye symptoms were reported by patients.
Abbreviation: IMRT, intensity-modulated radiation therapy.
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cordance with the observations of Rouviere [46] and with
the consensus recommendations [15]. Two marginal recur-
rences in the Michigan series were noted in the lateral ret-
ropharyngeal nodes (both occurred in patients with
oropharyngeal cancer), in which the cranialmost extent of
the retropharyngeal nodal targets was defined at the top of
C1, according to the observations of Rouviere [46] of the
locations of the lateral retropharyngeal nodes. Following
these observations, we currently define the retropharyngeal
nodes through the base of the skull. Interesting observations
about marginal or out-of-field recurrences were reported in
the series from the University of Iowa [43]. They found sev-
eral cases of recurrence in the contralateral level I in pa-
tients with lateral oral cavity and oropharyngeal cancer,
underscoring the need to include these nodes in locoregion-
ally advanced oral cancer. As more data about marginal re-
currences are accumulated, a better understanding and
higher certainty are expected to be gained in defining the
targets, which will lead to better tumor control and to an
ability to further spare noninvolved tissues.
IMRT for Laryngeal Carcinoma
Comparative dose distribution studies have shown that
IMRT can improve the target dose homogeneity in laryn-
geal and hypopharyngeal SCC while reducing the dose to
normal tissues at risk [48–50]. Clinical data on IMRT for
laryngeal and hypopharyngeal SCC are, however, quite
scarce and typically include patients with definitive and
postoperative irradiation with or without induction or con-
comitant chemotherapy. Chao et al. [11] and Dawson et al.
[9] reported very limited series with 10 patients in each
location, from which definitive conclusions cannot be
drawn. Yao et al. [43] reported on a series of 33 patients
with laryngeal SCC; the 2-year locoregional control rate
reached 85%, which was significantly lower than that ob-
served in oropharyngeal tumors [43]. Patient selection bias
cannot, however, be ruled out. A recent study reported the
feasibility of a dose-escalation trial in laryngeal SCC using
IMRT [51].
LESS NORMAL TISSUE MORBIDITY WITH IMRT
Several clinical studies assessed the utility of IMRT in pa-
rotid salivary gland sparing and in reducing xerostomia. At
the University of Michigan, the partial parotid gland doses
and volumes following multisegmental IMRT were corre-
lated with selective salivary output from each parotid gland
[5]. It was found that the output related to the mean doses to
the glands. The large majority of the glands that received a
mean dose26 Gy did not produce measurable saliva and
did not recover, whereas glands that received lower mean
doses produced variable salivary output that increased over
time. One year after radiotherapy, parotid glands that re-
ceived a moderate dose (mean dose, 17–26 Gy) recovered,
on average, to the pretreatment salivary production levels
[6]. When the doses to the parotid glands were very low, as
in cases of unilateral neck radiotherapy in which the con-
tralateral glands received mean doses 10 Gy, an “over-
compensation” of the damage to the ipsilateral glands was
noted in the second year post-therapy. In particular, the sal-
ivary flow rates from the contralateral glands exceeded, on
average, their pretreatment flow rates. This finding moti-
vates reducing the doses to the salivary glands to as low lev-
els as possible.
Data on dose response in the parotid glands are accumu-
lating [10, 52–55]. The common finding with all these data
is that a relationship seems to exist between the mean doses
to the glands and their residual salivary output. It is appar-
ent from the studies presented in the review that very dif-
ferent mean doses have been reported as thresholds beyond
which functional deficit occurs. These doses are in the
range of 20 Gy to almost 40 Gy. What is the reason for this
discrepancy? Several explanations are possible. One expla-
nation relates to different methodologies in assessing sali-
vary flow. Some studies used selective parotid outflow
measurements, others used whole mouth saliva, assuming
no contribution from the submandibular glands (which had
received high doses) and no contribution from the minor
salivary glands (whose output is relatively low), and some
studies used scintigraphy techniques to assess parotid gland
Table 3. Ocular toxicity after radiotherapy for ethmoid tumors
Radiation
technique n
Dry-eye
Drop in vision
<2/10Grade 1 Grade 2 >Grade 3
IMRT 39 2 3 2 2
2D 19 ? ? 5 0
3D 11 ? ? 2 2
Abbreviations: 2D, two-dimensional; 3D, three-dimensional; IMRT, intensity-modulated radiation therapy.
561Grégoire, De Neve, Eisbruch et al.
www.TheOncologist.com
function. Beyond this confounding factor, there are clinical
factors, beyond radiation dose, that affect the salivary out-
put but have not been taken into account in most of these
studies. These factors include dehydration, common in pa-
tients receiving HN radiotherapy, and various medicines
found to significantly affect salivary flow rates [5, 6]. An
additional important factor is one reported recently by in-
vestigators from the University Hospital in Groningen, The
Netherlands [56]. They irradiated different parts of rat sal-
ivary glands using high-precision proton radiation and
found regional differences in dose–salivary production re-
lationships. Such regional differences are likely to exist in
the human parotid glands, and they may be the reason for
different results found by researchers using different radio-
therapy techniques, which produce different dose distribu-
tions within the glands. Further research into intraparotid
regional differences in sensitivity to radiation is required
for a better understanding of radiation limits. Regardless of
the dose threshold, it is now apparent that spared glands not
only partly retain the salivary output, but the output in-
creases over time through at least 2 years after radiotherapy
[6], compared with generally no improvement over time
following standard radiotherapy, in which most of the pa-
rotid glands receive full radiotherapy doses.
Once a reasonable preservation of the salivary output is
achieved, can we expect similar improvements in patient-
reported xerostomia symptoms? The correlation between
salivary output from the major salivary glands and xerosto-
mia symptoms is significant, but is not very high. Part of the
reason for this less-than-straightforward relationship lies in
the contribution of the minor salivary glands. These glands
are scattered throughout the oral cavity, notably on the sur-
face of the palate, and produce much of the salivary mucin.
It has been found that the dose delivered to the oral cavity,
serving as a surrogate for the residual function of the minor
salivary glands (whose output cannot be measured), was an
independent factor in patient-reported xerostomia after ra-
diotherapy, similar to the importance of doses to the major
salivary glands [6]. An optimal practice is to add sparing of
the oral cavity as an objective in radiotherapy planning, in
addition to sparing of the parotid glands. An analysis at the
University of Michigan of a validated patient-reported xe-
rostomia questionnaire demonstrated that xerostomia im-
proved significantly over time, in tandem with an increase
in saliva production [6]. Two years following irradiation,
xerostomia reported by patients receiving parotid-sparing
bilateral neck radiation was only slightly worse than that in
patients receiving unilateral neck radiotherapy. Investiga-
tors at UCSF also reported an improvement to mild or no
xerostomia during the second year after IMRT for nasopha-
ryngeal cancer [41, 57]. It is apparent from all of these stud-
ies that the partial sparing of the salivary glands, made
possible by IMRT, achieves tangible gains both in the re-
tention of salivary production and in the symptoms of xe-
rostomia.
Another issue in the efforts to reduce xerostomia by
IMRT is the importance of the submandibular glands.
These glands lie anterior to the level II lymph node targets
in the neck. It is not possible to spare a substantial amount
of these glands while treating both sides of the neck (which
is required for all advanced HN cancer), resulting in no
measurable salivary output from these glands after radia-
tion [6]. Whether the use of technology like proton beams
would help is not yet known. Canadian investigators who
moved one submandibular gland to the submental space,
away from the radiotherapy fields, reported an impressive
reduction in xerostomia [58]. However, this technique has
not yet gained broad acceptance, as submandibular lymph
nodes are so closely related to the gland, or even into the
gland, that transposition may not only spare the organ at
risk but also the target tissue.
Additional potential functional gains from IMRT com-
pared with conventional radiotherapy include swallowing
and speech measures, reported to be superior using IMRT
compared with standard radiotherapy [59]. These potential
benefits may translate into improvements in broad aspects
of quality of life [60]. Thus, IMRT of HN cancer may
achieve broad improvements in quality of life rather than be
limited to improvements in xerostomia alone. Efforts to
identify the structures whose damage causes long-term dys-
phagia and aspiration, and to determine IMRT strategies
that may spare these structures without underdosing the tar-
gets, have been reported [61]. An assessment of the clinical
effect of these efforts is ongoing. In a recent study, how-
ever, a dosimetric comparison showed a much higher dose
to the larynx when the entire neck was irradiated with
IMRT than with a classical three-field setup with an ante-
rior field shielding the midline structures [62]. To avoid
such a perverse effect of IMRT, the laryngeal and hypopha-
ryngeal structures have to be delineated as organs at risk,
and assigned with a dose-volume constraint.
CONCLUSION
The data accumulated so far tend to indicate that this new
technique increases the therapeutic ratio by decreasing
treatment morbidity such as xerostomia. Whether all pa-
tients with HNSCC will benefit from IMRT is still un-
known. We hypothesize that patients with very early
disease (e.g., stage I tumors) or very extended disease (e.g.,
stage IVb tumors) will have less benefit from this tech-
nique, the former because a very high therapeutic ratio is
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already achieved and the latter because extended target vol-
umes will need to be irradiated.
The promising results of IMRT can, however, be
achieved only when all treatment conditions are met, for ex-
ample, optimal selection and delineation of the target vol-
umes and organs at risk, appropriate physical quality
control of the irradiation, and accurate patient setup with
the use of onboard imaging or more advanced imaging like
CT during therapy [28]. Because of the complexity of the
various tasks, it is thus likely that these conditions will be
met only in institutions having a large patient throughput.
Therefore, patient referral to those institutions with experi-
ence in treating many patients with IMRT of HN cancer is
recommended.
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